STAT+: Hope for Kendall Square’s lab market

STAT PlusNewsletterThe Readout Hope for Kendall Square’s lab market Drug pricing in Europe, AI deals for VC firms, and more biotech news from The Readout Manage alerts for this article Email this article Share this article By Elaine ChenJune 10, 2026 National Biotech Reporter Elaine Chen[email protected]Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. In today’s news, we have: pricing conundrums, lab demand, and drug shortages.Advertisement The need-to-know this morning Sanofi said it was halting a Phase 3 study of its drug riliprubart in a rare autoimmune disease after an interim analysis showed the therapy was not effective. It’s the latest blow to the French firm’s R&D efforts, which new CEO Belén Garijo has been brought in to revitalize. Parabilis Medicines, a developer of cancer medicines, raised $670 million in an initial public offering. It’s the largest-ever biotech IPO, topping obesity drugmaker Kailera Therapeutics’ $625 million debut in April. European countries at odds over drug-pricing policies In Europe, countries are grappling with what to do about drug prices as they contend with conflicting pressures. Aging populations and growing rates of chronic disease are straining their budgets, but, at the same, the U.S. and drugmakers are demanding they pay more for medicines. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, drug development, Drug prices, research Submit a correction requestReprints Elaine Chen National Biotech Reporter Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Newsletter Your morning rundown of the science, politics, and money driving biotech today Recommended D.C. Diagnosis June 9, 2026 STAT Plus: Trump’s health care affordability czar takes aim at hospitals The Readout June 9, 2026 Gilead and Merck’s latest trial success and flop Advertisement The Readout June 8, 2026 STAT Plus: Novo underwhelmed by drug it once fought Pfizer for Biotech June 8, 2026 STAT Plus: J&J spends $1 billion to enter KRAS race for cancer treatments Biotech June 8, 2026 STAT Plus: Combination of pancreatic cancer drugs from Tango, Revolution leads to high response rate Subscriber Picks